Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome

@article{Kim2012RufinamideAA,
  title={Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome},
  author={Shin Hye Kim and So-Hee Eun and Hoon-Chul Kang and Eun Ji Kwon and Jung Hye Byeon and Young Mock Lee and Joon Soo Lee and Baik-Lin Eun and Heung Dong Kim},
  journal={Seizure},
  year={2012},
  volume={21},
  pages={288-291}
}
PURPOSE To evaluate the efficacy of rufinamide as an add-on treatment in children and adolescents with Lennox-Gastaut syndrome (LGS). METHODS The study was an open-label, observational clinical trial of rufinamide as an add-on treatment in intractable LGS patients. This intent-to-treat trial included 4 weeks of scheduled titrated doses and a 12-week maintenance phase with a target dose of 20-40 mg/kg rufinamide, adjusted according to its effectiveness and tolerability after a baseline period… CONTINUE READING
9 Citations
17 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

A double - blind , randomized trial of topiramate in Lennox - Gastaut syndrome . Topiramate YL Study Group

  • A Arzimanoglou, J French, WT Blume, JH Cross, JP Ernst, M Feucht
  • Neurology
  • 1999

Similar Papers

Loading similar papers…